Yabing B. Du
No. 1 Jianshe East Road
Zhengzhou, 450052, China
Zhengzhou, 450052, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Erratum: HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma.
Journal: Hepatology communications
Published: January 02, 2026
HTRA1+ Macrophages Induce T-cell Egress through CRIP1/NF-κB/CXCL12 to Limit the Effects of Immunotherapy in Triple-Negative Breast Cancer.
Journal: Cancer immunology research
Published: September 18, 2025
CXCL2 affects macrophage antitumor function and immunotherapy efficacy in esophageal squamous cell carcinoma through calcium signaling.
Journal: Frontiers in immunology
Published: August 29, 2025
AKAP12 positive fibroblast determines immunosuppressive contexture and immunotherapy response in patients with TNBC by promoting macrophage M2 polarization.
Journal: Journal for immunotherapy of cancer
Published: October 03, 2024
Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial.
Journal: Cancer pathogenesis and therapy
Published: September 19, 2024
Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population.
Journal: Frontiers in oncology
Published: December 07, 2022
Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse.
Journal: Frontiers in oncology
Published: November 14, 2022
Exopolysaccharide from Weissella confusa J4-1 inhibits colorectal cancer via induction of cell cycle arrest.
Journal: International journal of biological macromolecules
Published: September 17, 2022
Predicting value on short-term outcome of various established risk prediction models in extracorporeal membrane oxygenation treated cardiogenic shock patients due to ST-segment elevation myocardial infarction
Journal: Zhonghua xin xue guan bing za zhi
Published: September 12, 2022
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.
Journal: International journal of cancer
Published: July 25, 2022
Last Updated: 09/26/2026